Biogen

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Retrieved on: 
Tuesday, April 2, 2024
Independent, Business school, Bachelor of Science, Engineering, Bristol Myers Squibb, Thayer School of Engineering, Immunology, Therapy, Corporate development, Corporation, True north, ICON PLC, Business, Dartmouth College, Biogen, ATP, Genzyme, Cardiology, Biomedical engineering, Novo Nordisk, Drug discovery, Tuck School of Business, Acquisition, University, MBBS, AbbVie, Bioverativ, ICON, CBO, Columbia University, Biology, MBA, Hidradenitis suppurativa, TRML, Partner, Military, Management

The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.

Key Points: 
  • The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.
  • The recent board appointments include Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors.
  • He has spent over a decade specializing in founding, building and investing in biotech companies.
  • Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

Autolus Therapeutics Announces Changes to its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Cubist Pharmaceuticals, DBV Technologies, MB, Alnylam Pharmaceuticals, Harvard Medical School, University of Cambridge, Faculty, Imperial College London, Development, GSK plc, Biologics license application, Hematology, Patient, ALL, Merck, Bristol Myers Squibb, Marketing, Biogen, Doctor of Philosophy, Bates College, Oxford Biomedica, Sarepta Therapeutics, Pharmaceutical medicine, Therapy, Swedish Orphan Biovitrum, Royal college, FDA, BLA, Autoimmunity, Economics, Food, Pharmaceutical industry

John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.

Key Points: 
  • John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.
  • We wish John much success with his new projects,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
  • He is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics and Gulf of Maine Research Institute.
  • Mr. Bonney has served as a director with many companies previously including Celgene, Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals.

Dyne Therapeutics Announces CEO Transition

Retrieved on: 
Monday, March 25, 2024
Arizona State University, California State University, Cell biology, Research, University, DM1, Dynamos, Biology, MBA, Biogen, Bioverativ, Therapy, DYN, DMD, Management

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamless transition.

Key Points: 
  • - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO -
    WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
  • Mr. Brumm will serve as an advisor to Dyne to help ensure a seamless transition.
  • Having worked extensively in rare diseases, I appreciate the meaningful impact that novel therapeutics can have on a patient community,” said Mr. Cox.
  • Most recently, he served as CEO of Repertoire Immune Medicines and its predecessor from 2019 until 2022.

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

Retrieved on: 
Wednesday, March 13, 2024
AAV, ALS, Assistant, Central nervous system, University, Florida College, SOD1, CNS, Running, Traffic barrier, IND, Biogen, DSM-IV codes, Therapy, CMO, Medical director, University of Florida, Pharmaceutical industry

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024.

Key Points: 
  • LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024.
  • During his tenure, he built and developed teams focused on neuromuscular and movement disorders, overseeing strategy for these areas across Biogen R&D.
  • Prior to joining Biogen, Ferguson was Assistant Professor of Neurology, Shriners Pediatric Research Center and Temple University School of Medicine.
  • Voyager represents for me an extraordinary opportunity to fulfill this mission.”

Mosaic Biosciences Expands Its Leading Drug Discovery and Development Expertise

Retrieved on: 
Tuesday, April 2, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biogen, Obesity, Drug discovery, Cancer immunotherapy, Diabetes, Malavi, History, BMS, Doctor of Philosophy, Bristol Myers Squibb, CTI, Therapy, Genomics, NASH, GNF, CSO, Antibody, Inflation, Autoimmunity, DSM-IV codes, Pharmaceutical industry

Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.

Key Points: 
  • Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.
  • Both recognized leaders join the company as it grows to meet increased demand for its comprehensive and integrated drug discovery research services.
  • “I am excited to leverage my drug discovery and clinical development expertise to further position Mosaic Biosciences as the partner of choice for discovering innovative protein therapeutics in a disease agnostic manner,” said Malavi.
  • “Mosaic Biosciences has a strong history of technical innovations and partner support that makes it a leader in the discovery of successful next-generation protein therapeutics,” said Scott.

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease

Retrieved on: 
Tuesday, March 26, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Neurology, Multiple sclerosis, Biomarker, Neuroscience, Parkinson's disease, Biogen, Safety, LUMA, Medtech, Medical imaging

Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.

Key Points: 
  • Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.
  • As part of the agreement, Biogen will licence KonectomTM to Indivi, a smartphone-based digital biomarker platform that assesses neurological functions remotely for more precise, frequent measurement of disease evolution.
  • In addition, Biogen and Indivi aim to develop and validate novel digital endpoints in Parkinson’s disease as well as explore additional disease areas for endpoint development leveraging KonectomTM.
  • Indivi uses advanced computational and statistical modelling methods to potentially yield more precise measures of progression of Parkinson’s disease with improved signal-to-noise properties.

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Thursday, March 21, 2024
Class Action Lawsuit, Professional Services, Legal, BIIB, Biogen, News

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB).
  • Investors who purchased Biogen Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/BIIB .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Principal, RAPS, University, Science, Atlas, ARCH Venture Partners, Drug discovery, Patient, Biogen, Molecular biology, Senior advisor, Biochemistry, Therapy, DSM-IV codes, RNA interference, Atlas Venture, Multimedia, Third Rock Ventures, Takeda Oncology, Biotechnology Innovation Organization, Pharmaceutical industry

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of John Maraganore, Ph.D., to its Board of Directors.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of John Maraganore, Ph.D., to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20240319245625/en/
    “As Rapport sets out to build a leading precision neuroscience company, we are incredibly fortunate to have Dr. Maraganore join our board,” said Abraham Ceesay, Chief Executive Officer of Rapport.
  • “John is among a few visionary leaders who have guided a new modality from concept to a dynamic platform for drug discovery.
  • Dr. Maraganore served as founding CEO of Alnylam from 2002 to 2021, where he led the development of a novel class of medicines, referred to as RNAi therapeutics.

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Thursday, March 14, 2024
Class Action Lawsuit, Professional Services, Legal, BIIB, Biogen, News

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB).
  • Investors who purchased Biogen Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/BIIB .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.